The Association of Blood Biomarkers and Body Mass Index in Knee Osteoarthritis: A Cross-Sectional Study

• Published in: Cartilage 2022-01, Vol.13 (1), p.19476035211069251-19476035211069251
• Main Authors: Schadler, Paul, Lohberger, Birgit, Thauerer, Bettina, Faschingbauer, Martin, Kullich, Werner, Stradner, Martin Helmut, Leithner, Andreas, Ritschl, Valentin, Omara, Maisa, Steinecker-Frohnwieser, Bibiane
• Format: Article
• Language: English
• Subjects: Biomarkers; Body Mass Index; Cross-Sectional Studies; Humans; Leptin; Metabolic Syndrome - complications; Obesity - complications; Original; Osteoarthritis, Knee - complications; Resistin
• ISSN: 1947-6035; 1947-6043
• DOI: 10.1177/19476035211069251

Objective Despite massive efforts, there are no diagnostic blood biomarkers for knee osteoarthritis (KOA). This study investigated several candidate diagnostic biomarkers and the metabolic phenotype in end-stage KOA in the context of obesity. Design In this cross-sectional study, adult patients undergoing knee arthroplasty were enrolled and KOA severity was assessed using the Lequesne index. Blood biomarkers with an important role in obesity, the metabolic syndrome, or KOA (oxidized form of low-density lipoprotein [oxLDL], advanced glycation end product [AGE], soluble AGE receptor [sRAGE], fatty acid binding protein 4 [FABP4], phospholipase A2 group IIA [PLA2G2A], fibroblast growth factor 23 [FGF-23], ghrelin, leptin, and resistin) were measured using enzyme-linked immunosorbent assay (ELISA; n = 70) or Luminex technique (subgroup of n = 35). H1-NMR spectroscopy was used for the quantification of metabolite levels (subgroup of n = 31). The hip-knee-ankle angle was assessed. Multivariable and multivariate regression analysis was used to examine the relationship of biomarkers with body mass index (BMI) and KOA severity in complete case and multiple imputation analysis. Results While most of the investigated biomarkers were not associated with KOA severity, FABP4 and leptin were found to correlate with BMI and gender. Resistin was associated with Lequesne index in complete case analysis. Using a targeted metabolomics approach, BMI-dependent changes in the metabolome were hardly visible. Conclusions Our findings confirm studies on FABP4, leptin, and resistin with regard to obesity and the metabolic syndrome. There was no association of the investigated biomarkers with KOA severity, most likely due to the patient selection (end-stage KOA patients). Based on this absence of BMI-dependent changes in the metabolome, we might assume that BMI is not correlated with KOA severity in this specific patient group.